Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Aafke H. Honkoop"'
Autor:
C. Willemien Menke-van der Houven van Oordt, Marc B. I. Lobbes, Cristina Guerrero Paez, Aafke H. Honkoop, Monique E. M. M. Bos, Marjolein L. Smidt, Mireille J. M. Broeders, Vivianne C. G. Tjan-Heijnen, Anouk H. Eijkelboom, Linda de Munck, Luc J. A. Strobbe, Sabine Siesling, Jelle Wesseling, J. Verloop, Maud Bessems, Marjanka K. Schmidt, Marie-Jeanne T. F. D. Vrancken Peeters, Pieter J. Westenend, Desirée H.J.G. van den Bongard, Sabine C. Linn
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-12 (2021)
the NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium 2021, ' Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study ', Journal of Hematology and Oncology, vol. 14, no. 1, 64 . https://doi.org/10.1186/s13045-021-01073-7
Journal of Hematology & Oncology, 14(1):64. BioMed Central
Journal of Hematology and Oncology, 14(1). BMC
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 14, 1
Journal of Hematology & Oncology, 14
Journal of Hematology and Oncology, 14(1):64. BioMed Central Ltd.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 14(1):64. BioMed Central
Journal of Hematology and Oncology, 14(1):64. BioMed Central
the NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium 2021, ' Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study ', Journal of Hematology and Oncology, vol. 14, no. 1, 64 . https://doi.org/10.1186/s13045-021-01073-7
Journal of Hematology & Oncology, 14(1):64. BioMed Central
Journal of Hematology and Oncology, 14(1). BMC
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 14, 1
Journal of Hematology & Oncology, 14
Journal of Hematology and Oncology, 14(1):64. BioMed Central Ltd.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 14(1):64. BioMed Central
Journal of Hematology and Oncology, 14(1):64. BioMed Central
Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment recommendations from week 12 of 2
Autor:
Peter Nieboer, Petra H.M. Peeters, Sophie A Kurk, Marion Jourdan, Cornelis J. A. Punt, Anne M. May, Miriam Koopman, Aafke H. Honkoop, Bram Dorresteijn, Jeroen W.G. Derksen, Robert S. De Jong, Ankie M.T. van der Velden
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 4, Pp 919-928 (2020)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, 11(4), 919-928. Wiley-Blackwell
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, 11(4), 919-928. Wiley-Blackwell
Background Skeletal muscle mass (SMM) loss is common in metastatic colorectal cancer (mCRC) patients and associated with poor clinical outcomes, including increased treatment‐related toxicities and reduced survival. Muscle loss may contribute to re
Autor:
WK de Roos, Frans L. G. Erdkamp, H de Graaf, IE van Hellemond, M. de Boer, M. van der Sangen, Carolien H. Smorenburg, Aafke H. Honkoop, F.W.P.J. van den Berkmortel, Carine Seynaeve, VC Tjan-Heijnen, Astrid C P Swinkels, Pgm Peer, A.L.T. Imholz, Judith R. Kroep, Sabine C. Linn
Publikováno v:
Cancer Research. 79:P4-14
Background: The phase III DATA study (NCT00301457) investigates the efficacy of 6 versus 3 years of adjuvant anastrozole after an initial 2-3 year treatment with tamoxifen in postmenopausal women with breast cancer. A reduced bone mineral density (BM
Autor:
Mette S. van Ramshorst, Aafke H. Honkoop, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Caroline M.P.W. Mandigers, Sabine C. Linn, Agnes J. van de Wouw, Gabe S. Sonke, I.A.M. Mandjes, Erik van Werkhoven, Anna van der Voort, Jelle Wesseling, Inge Kemper, Laurence J. C. van Warmerdam, Lidwine W. Tick, Irma M. Oving
Publikováno v:
The Lancet Oncology. 19:1630-1640
Summary Background The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared wi
Autor:
Vivianne C. G. Tjan-Heijnen, Laurence J. C. van Warmerdam, Marta Lopez-Yurda, Edith van Druten, Hiltje de Graaf, Anouk K. M. Claessens, Aafke H. Honkoop, Maurice J.C. van der Sangen, Monique E. M. M. Bos, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Frans L. G. Erdkamp
Publikováno v:
Breast Cancer Research and Treatment, 172(2), 413-423. Springer New York
Breast Cancer Research and Treatment, 172(2), 413-423. Springer, Cham
Breast Cancer Research and Treatment, 172(2), 413-423. Springer, Cham
PurposeWe determined if intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment in patients with HER2-negative, advanced breast cancer.MethodsPatients were randomized to 2x4 cycles or continuous 8 c
Autor:
Mathijs P. Hendriks, Carmen C. van der Pol, Kees C W J Ebben, Maud Bessems, Aafke H. Honkoop, J. Verloop, Xander A. A. M. Verbeek, Ernest J. T. Luiten, Melle Sieswerda, Joan B. Heijns
Publikováno v:
JCO Clinical Cancer Informatics
PURPOSE Tumor boards, clinical practice guidelines, and cancer registries are intertwined cancer care quality instruments. Standardized structured reporting has been proposed as a solution to improve clinical documentation, while facilitating data re
Autor:
Anouk K. M. Claessens, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Marta Lopez-Yurda, Vivianne C. G. Tjan-Heijnen, Frans L. G. Erdkamp, Hiltje de Graaf, Monique E. M. M. Bos, Jeanette M. Bouma
Publikováno v:
Acta Oncologica, 59(6), 713-722. Informa Healthcare
Acta Oncologica, 59(6), 713-722. Routledge/Taylor & Francis Group
Acta Oncologica, 59(6), 713-722. Routledge/Taylor & Francis Group
Background: Previously, we showed that reintroduction of the same (first-line) chemotherapy at progression could only partially make up for the loss in efficacy as compared to continuously delivered first-line chemotherapy. Here, we report the probab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68252ff0682fa6aee566b737eaa479a1
https://pure.eur.nl/en/publications/4999cf0a-42b3-4873-a80a-1840106c0e50
https://pure.eur.nl/en/publications/4999cf0a-42b3-4873-a80a-1840106c0e50
Autor:
Awg van der Velden, Jms Bartlett, I Bozovic-Spasojevic, MM Vleugel, Nicola S. Russell, Isabel T. Rubio, S Hilsenbeck, Sharon H. Giordano, C. Poncet, Miguel Henriques Abreu, A Wolff, Chm van Deurzen, C. Van Poznak, Barbro Linderholm, Larissa A. Korde, David Cameron, Idm den Hoed, Carolien P. Schröder, N Dijkstra, KJ Ruddy, Aafke H. Honkoop, D Morganstern, Jwm Martens, Fatima Cardoso, K Aalders, Oliver Bogler, Tineke J. Smilde, T Goulioti, M van 't Riet, Konstantinos Tryfonidis, E van Leeuwen-Stok
Publikováno v:
Cancer Research. 78:P5-23
BACKGROUND: Through the International Male Breast Cancer Program, a prospective registry for male BC was created with the goals of evaluating 1) the clinical and biological features of this disease and 2) assessing feasibility of a prospective therap
Autor:
G.A.P. Nieuwenhuijzen, R.A. Hellingman, Franchette W P J van den Berkmortel, S. Hovenga, H.M. Oosterkamp, T. van Dalen, Sabine C. Linn, E.J. van Dulken, Rudi M. H. Roumen, Maurice J.C. van der Sangen, R.C. van Doorn, M.O. den Boer, R. den Toom, Carolien H. Smorenburg, J.J.M. van der Hoeven, Aafke H. Honkoop, Irene E. G. van Hellemond, H. Potthoff, R. Koelemij, Frans L. G. Erdkamp, A. van Bochove, W.G. van Leeuwen-Breuk, R.J.B. Blaisse, A.M.T. van der Velden, Yvonne Kamm, E.J.C. Vriens, Judith R. Kroep, Erik W. Muller, W.J.B. Mastboom, R. van Hillegersberg, P.C. van der Velden, T. van Voorthuizen, Vivianne C. G. Tjan-Heijnen, J.M. Meerum Terwogt, M.M. Vleugel, A. Vos, J.J. Jansen, Jos J. E. M. Kitzen, G.S. Madretsma, R. Vree, J.K.S. Nuytinck, Luc J. A. Strobbe, J.H. van Dam, P.H.A. Nijhuis, Wilfred K. de Roos, P.P.J.B.M. Schiphorst, B. Jas, E.E.M. Schepers, Q. van Rossum-Schornagel, Petronella G. M. Peer, C.J. van Groeningen, J.G. Haasjes, M.J. Agterof, E.A. Kouwenhoven, Alexander L T Imholz, Caroline M. Seynaeve, M.A. Davidis-van Schoonhoven, M.A.J. de Roos, M.J.P.M. Govaert, J.M.A. Ketel, J.M.G.H. van Riel, M. Jagers, A.J. van Overbeeke, Aart Beeker, J.K. Maring, G.J. Veldhuis, J.W.S. Merkus, Maaike de Boer, Onno R. Guicherit, H.B.A.C. Stockmann, E. Janssens van Vliet, J. de Boer, D.F.S. Kehrer, I.E. Arntz, N.G.J. van Diemen, Koop Bosscha, Hiltje de Graaf, F.A.A. Valster, E.E.M. Weernink, C.T.A.M. van Rossum, M.A. van Dijk, B.C. Tanis, Astrid C P Swinkels, E.J.M. Siemerink, D.W. Sommeijer
Publikováno v:
Tjan-Heijnen, V C G, van Hellemond, I E G, Peer, P G M, Swinkels, A C P, Smorenburg, C H, van der Sangen, M J C, Kroep, J R, De Graaf, H, Honkoop, A H, Erdkamp, F L G, van den Berkmortel, F W P J, de Boer, M, de Roos, W K, Linn, S C, Imholz, A L T, Seynaeve, C M & Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators 2017, ' Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA) : a randomised, phase 3 trial ', The Lancet Oncology, vol. 18, no. 11, pp. 1502-1511 . https://doi.org/10.1016/S1470-2045(17)30600-9
The Lancet Oncology, 18(11), 1502-1511
Lancet Oncology, 18, 11, pp. 1502-1511
LANCET ONCOLOGY, 18(11), 1502. Lancet Publishing Group
The Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet oncology, 18(11), 1502-1511. Elsevier Science
Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet Oncology, 18, 1502-1511
The Lancet Oncology, 18(11), 1502-1511
Lancet Oncology, 18, 11, pp. 1502-1511
LANCET ONCOLOGY, 18(11), 1502. Lancet Publishing Group
The Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet oncology, 18(11), 1502-1511. Elsevier Science
Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet Oncology, 18, 1502-1511
Item does not contain fulltext BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment perio
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS